Barcelona had more than 10,000 presentations but we could cover only a fraction of these. So we asked Pablo Tebas, M.D. to give us an overview of what he took home from Barcelona.
HAART has led to declines in the incidence of other malignancies such as Kaposi's sarcoma and non-Hodgkin's lymphoma, but its effect on HPV-associated anogenital cancers is unclear. Dr. Judith Aberg analyzes a recent study.
We know that potent antiretroviral therapy will reduce transmission from a woman to her HIV-positive baby. But are studies in the developing world that give therapy to the mother during labor without intention of continuing afterwards ethical? Dr. Judith Aberg looks at one such study.
Quite a few presentations at this year's conference revolved around tenofovir, as researchers reported on its effectiveness in a wide variety of treatment situations. One widely discussed study compared a drug regimen with tenofovir to one with d4T, and found that tenofovir worked just as well, but with fewer side effects. More from Cal Cohen, M.D.
Hope for negative women who want to have a child with an HIV-positive man! In over 4,000 inseminations in more than 1,500 couples there were no transmissions of HIV. Dr. Judy Aberg reports on this presentation.
Dramatic results for patients with both HIV and hepatitis B using tenofovir.
Read Andrew Pavia's coverage of this important study.
Results from the important T-20 studies with treatment-experienced patients are in and it looks like it will be approved soon. Pablo Tebas, M.D. reports.
A Boston-area HIV patient whose immune system had remarkably reconstituted suffered a rapid clinical decline after he became superinfected with a related strain of HIV. Keith Henry, M.D. provides the details of Dr. Bruce Walker's findings.
Research is still plodding ahead on the different ways that treatment interruptions may improve care. Read Cal Cohen's update from Barcelona on the very latest research.
From Marrakech to Doha: Pablo Tebas, M.D. covers an informative crash course on patent law.
The results of a recent trial add to the rationale of a more conservative approach to treatment, in which the initiation of therapy is delayed until CD4+ cell counts consistently drop below 350. Read Pablo Tebas, M.D.'s coverage for more details.
Protease inhibitors are taking a big hit as first-line agents in the
treatment of antiretroviral-naïve patients. Pablo Tebas, M.D. says the studies are finally catching up to clinical practice. Click here to read more.